Researcher
Sandrine Degryse
- Disciplines:Systems biology
Affiliations
- Laboratory of Molecular Biology of Leukemia (VIB-KU Leuven) (Division)
Member
From1 Sep 2012 → 31 Dec 2017
Projects
1 - 1 of 1
- The JAK3 kinase as a therapeutic target in T-cell acute lymphoblastic leukemia.From1 Sep 2012 → 31 Dec 2017Funding: IWT personal funding - strategic basic research grants
Publications
1 - 10 of 12
- Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia (vol 32, pg 788, 2018)(2018)
Authors: Sandrine Degryse, CE de Bock, S Demeyer, Inge Govaerts, Simon Bornschein, Delphine Verbeke, K Jacobs, S Binos, DA Skerrett-Byrne, HC Murray, et al.
Pages: 2731 - 2731 - Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia(2018)
Authors: Sandrine Degryse, Charles De Bock, Sofie Demeyer, Inge Govaerts, Simon Bornschein, Delphine Verbeke, Jan Cools
Pages: 788 - 800 - HOXA9 cooperates with activated JAK/STAT signaling to drive leukemia development(2018)
Authors: Charles De Bock, Sofie Demeyer, Sandrine Degryse, Delphine Verbeke, Marlies Vanden Bempt, Ellen Geerdens, Simon Bornschein, Rik Gijsbers, Jan Cools
Pages: 616 - 631 - Mutant JAK3 signaling is increased by loss of wild type JAK3 or by acquiring secondary JAK3 mutations in T-ALL(2018)
Authors: Sandrine Degryse, Simon Bornschein, Charles De Bock, Marlies Vanden Bempt, Sofie Demeyer, Ellen Geerdens, Jan Cools
Pages: 421 - 425 - De rol van JAK3 mutaties in T cel acute lymfatische leukemie(2017)
Authors: Sandrine Degryse, Jan Cools
- Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors(2016)
Authors: Antonis Dagklis, Sofie Demeyer, Jolien De Bie, Enrico Radaelli, Daphnie Pauwels, Sandrine Degryse, Olga Gielen, Carmen Vicente, Roel Vandepoel, Ellen Geerdens, et al.
Pages: 2642 - 2654 - Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors(2016)
Authors: Sofie Demeyer, Jolien De Bie, Sandrine Degryse, Ellen Geerdens, Anne Uyttebroeck, Nancy Boeckx, Charles De Bock, Jan Cools
Pages: 2642 - 2654 - Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities(2015)
Authors: Sandrine Degryse, Jan Cools
Pages: 29022 - 34 - Targeted sequencing identifies association between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia(2015)
Authors: Carmen Vicente, Michaël Broux, Ellen Geerdens, Sandrine Degryse, Sofie Demeyer, Peter Vandenberghe, Jan Cools
Pages: 1301 - 10 - JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia(2015)
Authors: Sandrine Degryse, Jan Cools
Pages: 91